Diane Bovenkamp's guest appearances

Diane Bovenkamp

Straight from a Scientist Medical Research Education and Discussion Podcast

See What We See

Alex Israel

Jeff Locke

Ken Clark

Stephanie Martin

Rachel Paul

Maui Jim

Michael Webb

Alyssa Olenick

Tayler Catherine

Elizabeth Head

Mohanish Deshmukh

Cynthia Lemere

Charles Glabe

Lea T. Grinberg

Anton Rogachov

OwlTail

In this episode, Lorne &amp; Martin spoke with Dr. Diane Bovenkamp, VP of Scientific Affairs at BrightFocus. Dr. Diane is an expert of Macular Degeneration and she spent time in part one of this two part episode speaking to some of the risks that UV light pose to the health of the eye. *Note: The information shared in this podcast is strictly informational in nature and not to be taken as medical advice. Please contact your eye care practitioner for any medical advice or emergency.If you missed Part One, check it out here! BrightFocus - www.brightfocus.org Phone: 1-800-437-2423Fax: (301) 258-9454E-mail: info@brightfocus.orgFacebookInstagramLinkedInTwitterSpecial thank you to the sponsor of this episode:Transitions Adaptive lenses that automatically adjust from clear to dark through activation from UV light.Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.

In this episode, Lorne &amp; Martin spoke with Dr. Diane Bovenkamp, VP of Scientific Affairs at BrightFocus. Dr. Diane is an expert of Macular Degeneration and she spent time in part one of this two part episode speaking to some of the risks that UV light pose to the health of the eye. *Note: The information shared in this podcast is strictly informational in nature and not to be taken as medical advice. Please contact your eye care practitioner for any medical advice or emergency. If you missed Part One, check it out <a href="https://www.ontario-opticians.com/podcast/episode/4a7534f5/episode-9-bright-focus-interview-with-dr-diane-bovenkamp-part-one" rel="nofollow" target="_blank">here!</a> BrightFocus - <a href="https://www.brightfocus.org/" rel="nofollow" target="_blank">www.brightfocus.org </a>Phone: 1-800-437-2423 Fax: (301) 258-9454 E-mail: <a href="mailto:info@brightfocus.org">info@brightfocus.org</a><a href="https://www.facebook.com/BrightFocusFoundation" rel="nofollow" target="_blank">Facebook</a> <a href="https://www.instagram.com/brightfocus/" rel="nofollow" target="_blank">Instagram</a> <a href="https://www.linkedin.com/company/brightfocus-foundation/" rel="nofollow" target="_blank">LinkedIn</a> <a href="https://twitter.com/_BrightFocus" rel="nofollow" target="_blank">Twitter</a>Special thank you to the sponsor of this episode:<a href="https://www.transitions.com/en-ca/" rel="nofollow" target="_blank">Transitions</a> Adaptive lenses that automatically adjust from clear to dark through activation from UV light. Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.

Episode 9: Bright Focus - Interview with Dr. Diane Bovenkamp (Part Two)

In this episode, Lorne &amp; Martin spoke with Dr. Diane Bovenkamp, VP of Scientific Affairs at BrightFocus. Dr. Diane is an expert of Macular Degeneration and she spent time in part one of this two part episode speaking to some of the risks that UV light pose to the health of the eye. *Note: The information shared in this podcast is strictly informational in nature and not to be taken as medical advice. Please contact your eye care practitioner for any medical advice or emergency.BrightFocus - www.brightfocus.org Phone: 1-800-437-2423Fax: (301) 258-9454E-mail: info@brightfocus.orgFacebookInstagramLinkedInTwitterTransitions Adaptive lenses that automatically adjust from clear to dark through activation from UV light.Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.

In this episode, Lorne &amp; Martin spoke with Dr. Diane Bovenkamp, VP of Scientific Affairs at BrightFocus. Dr. Diane is an expert of Macular Degeneration and she spent time in part one of this two part episode speaking to some of the risks that UV light pose to the health of the eye. *Note: The information shared in this podcast is strictly informational in nature and not to be taken as medical advice. Please contact your eye care practitioner for any medical advice or emergency. BrightFocus - <a href="https://www.brightfocus.org/" rel="nofollow" target="_blank">www.brightfocus.org </a>Phone: 1-800-437-2423 Fax: (301) 258-9454 E-mail: <a href="mailto:info@brightfocus.org">info@brightfocus.org</a><a href="https://www.facebook.com/BrightFocusFoundation" rel="nofollow" target="_blank">Facebook</a> <a href="https://www.instagram.com/brightfocus/" rel="nofollow" target="_blank">Instagram</a> <a href="https://www.linkedin.com/company/brightfocus-foundation/" rel="nofollow" target="_blank">LinkedIn</a> <a href="https://twitter.com/_BrightFocus" rel="nofollow" target="_blank">Twitter</a><a href="https://www.transitions.com/en-ca/" rel="nofollow" target="_blank">Transitions</a> Adaptive lenses that automatically adjust from clear to dark through activation from UV light. Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.

Episode 9: Bright Focus - Interview with Dr. Diane Bovenkamp (Part One)

Frank LaFerla

Bruce Lamb

This week’s episode marks the 1st of a series focused on Alzheimer’s disease (AD) research.  All episodes were recorded in San Diego, CA, where Connor Wander attended the  BrightFocus Alzheimer’s Disease Fast Track conference, followed by the Society for Neuroscience annual meeting. The Society for Neuroscience (SfN) is a well-known conference, drawing 28 thousand people annually.  In contrast, AD Fast Track is a much smaller conference put on by BrightFocus, a foundation built to support AD and glaucoma research and awareness.  Many of the speakers at the event were directly supported by BrightFocus (Lamb, Brinton, Head, Grinberg). Alzheimer’s disease research is reinventing itself in the wake of past failures.  New understandings of disease complexity, paired with recent advances in technology and a renewed surge in funding for research fuels new hope for a cure or treatment.  Yet we aren’t putting all our eggs in one basket.  This series will explore Alzheimer’s disease research and the variety of research strategies with the common goal of curing Alzheimer’s disease.   In This Episode Listen in to hear an overview of the BrightFocus AD Fast Track conference and current standing of Alzheimer’s disease research.  We also focus on animal models of Alzheimer’s disease. @6:07 Dr. Diane Bovenkamp introduces BrightFocus and the AD Fast Track Conference. @21:00 Dr. Frank LaFerla breaks down amyloid beta and tau in Alzheimer's disease research. @37:31 Dr. Bruce T. Lamb describes the MODEL-AD project, which seeks to better simulate Alzheimer's disease in animal models. Special thanks to all podcasts guests and to Martha and Rachel from BrightFocus!     More Information Listen to a brief summary of Alzheimer’s disease signs and symptoms with Dr. Diane Bovenkamp. Find more quick chats on the BrightFocus Foundation website, including some tips and support for Alzheimer’s disease caregivers. The amyloid cascade hypothesis is commonly discussed in Episode 41: Alzheimer’s disease roundtable. Listen to a discussion of Amyloid beta’s putative role as an ancient ant-microbial peptide in the brain in Episode 13: Amyloid Beta: Villain, or Hero in Alzheimer’s Disease? This possible role for Amyloid beta is important in the Amyloid cascade hypothesis; the idea that amyloid beta is the first thing to go wrong in AD, and triggers a chain reaction causing tau to aggregate and kill neurons.  This is a commonly discussed hypothesis in Alzheimer’s research, and is often referenced in this series. Learn more with a detailed infographic on the Amyloid cascade hypothesis.  It’s in a perspective piece discussing the recent developments in AD research by Biogen, and Eisai, two companies working on Alzheimer’s disease therapeutics like such as anti-amyloid or anti-tau antibodies, which have shown some promise in AD clinical trials. For more in-depth analysis of developments in AD and other neurodegenerative diseases, check out Alzforum.org for Alzheimer’s disease background reading.     Any other questions?  Let us know!  We appreciate your feedback. You can now support the podcast at https://www.patreon.com/sfspodcast.  Many thanks to our past and present supporters!  Thanks to Plant Warrior for their support.  Use discount code SFS10 at checkout for 10% off your purchase of plant-based protein.

This week’s episode marks the 1st of a series focused on Alzheimer’s disease (AD) research.  All episodes were recorded in San Diego, CA, where Connor Wander attended the <a href="https://www.brightfocus.org/alzheimers-disease/news/alzheimers-fast-track-shaping-new-generation-alzheimers-researchers" rel="nofollow" target="_blank"> BrightFocus Alzheimer’s Disease Fast Track conference</a>, followed by the Society for Neuroscience annual meeting. The <a href="https://www.sfn.org/" rel="noopener nofollow" target="_blank">Society for Neuroscience</a> (SfN) is a well-known conference, drawing 28 thousand people annually.  In contrast, AD Fast Track is a much smaller conference put on by BrightFocus, a foundation built to support AD and <a href="https://www.aao.org/eye-health/diseases/what-is-glaucoma" rel="noopener nofollow" target="_blank">glaucoma</a> research and awareness.  Many of the speakers at the event were directly supported by BrightFocus (Lamb, Brinton, Head, Grinberg). Alzheimer’s disease research is reinventing itself in the wake of past failures.  New understandings of disease complexity, paired with recent advances in technology and a renewed surge in funding for research fuels new hope for a cure or treatment.  Yet we aren’t putting all our eggs in one basket.  This series will explore Alzheimer’s disease research and the variety of research strategies with the common goal of curing Alzheimer’s disease. In This Episode Listen in to hear an overview of the BrightFocus AD Fast Track conference and current standing of Alzheimer’s disease research.  We also focus on animal models of Alzheimer’s disease. @6:07 <a href="https://www.straightfromascientist.com/dr-diane-bovenkamp-vp-of-scientific-affairs-at-brightfocus/" rel="noopener nofollow" target="_blank">Dr. Diane Bovenkamp</a> introduces <a href="https://www.brightfocus.org" rel="noopener nofollow" target="_blank">BrightFocus</a> and the AD Fast Track Conference. @21:00 <a href="https://www.straightfromascientist.com/dr-frank-laferla-uc-irvine/" rel="noopener nofollow" target="_blank">Dr. Frank LaFerla</a> breaks down amyloid beta and tau in Alzheimer's disease research. @37:31 <a href="https://www.straightfromascientist.com/dr-bruce-t-lamb-indiana-university/" rel="noopener nofollow" target="_blank">Dr. Bruce T. Lamb</a> describes the <a href="https://model-ad.org/" rel="noopener nofollow" target="_blank">MODEL-AD</a> project, which seeks to better simulate Alzheimer's disease in animal models. Special thanks to all podcasts guests and to Martha and Rachel from BrightFocus! More Information Listen to a brief summary of <a href="https://www.brightfocus.org/alzheimers/podcast/signs-and-symptoms-alzheimers-disease" rel="noopener nofollow" target="_blank">Alzheimer’s disease signs and symptoms</a> with Dr. Diane Bovenkamp. Find more quick chats on the <a href="https://www.brightfocus.org/news/multimedia?type=audio&amp;field_disease_tid=2" rel="noopener nofollow" target="_blank">BrightFocus Foundation website</a>, including some tips and support for Alzheimer’s disease caregivers. The amyloid cascade hypothesis is commonly discussed in Episode 41: Alzheimer’s disease roundtable. Listen to a discussion of Amyloid beta’s putative role as an ancient ant-microbial peptide in the brain in <a href="https://www.straightfromascientist.com/amyloid-beta-villain-or-hero-in-alzheimers-disease/" rel="noopener nofollow" target="_blank">Episode 13: Amyloid Beta: Villain, or Hero in Alzheimer’s Disease?</a> This possible role for Amyloid beta is important in the Amyloid cascade hypothesis; the idea that amyloid beta is the first thing to go wrong in AD, and triggers a chain reaction causing tau to aggregate and kill neurons.  This is a commonly discussed hypothesis in Alzheimer’s research, and is often referenced in this series. Learn more with a detailed <a href="https://www.nature.com/articles/d42473-018-00068-2" rel="noopener nofollow" target="_blank">infographic</a> on the Amyloid cascade hypothesis.  It’s in a perspective piece discussing the recent developments in AD research by <a href="https://www.biogen.com/en_us/home.html" rel="noopener nofollow" target="_blank">Biogen</a>, and <a href="https://us.eisai.com/" rel="noopener nofollow" target="_blank">Eisai</a>, two companies working on Alzheimer’s disease therapeutics like such as anti-amyloid or anti-tau antibodies, which have shown some promise in AD clinical trials. For more in-depth analysis of developments in AD and other neurodegenerative diseases, check out <a href="https://www.alzforum.org/" rel="noopener nofollow" target="_blank">Alzforum.org</a> for Alzheimer’s disease background reading. Any other questions?  <a href="https://www.straightfromascientist.com/contact-us/" rel="noopener nofollow" target="_blank">Let us know!</a>  We appreciate your feedback. You can now support the podcast at <a href="https://www.patreon.com/sfspodcast" rel="noopener nofollow" target="_blank">https://www.patreon.com/sfspodcast</a>.  Many thanks to our past and present supporters!  Thanks to <a href="https://www.plantwarrior.co/" rel="noopener nofollow" target="_blank">Plant Warrior</a> for their support.  Use discount code SFS10 at checkout for 10% off your purchase of plant-based protein.

Ep. 39: Alzheimer’s Disease Research Part I with Drs. Diane Bovenkamp, Frank LaFerla, and Bruce Lamb